登录

Lexaria测试DehydrateTECH GLP-1产品的减肥和糖尿病效果

Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes

seekingalpha 2024-03-06 01:39 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Michail_Petrov-96/iStock via Getty Images Lexaria (NASDAQ:LEXX) said it plans to run an animal study evaluating formulations of its products DehydraTECH-GLP-1, which includes Novo Nordisk's semaglutide or liraglutide, and DehydraTECH-CBD in the treatment of weight loss and diabetes. DehydraTECH-GLP-1 is a GLP-1 drug processed with the company’s DehydraTECH drug delivery technology, while DehydraTECH-CBD is a cannabidiol product.

Michail\u Petrov-96/iStock通过Getty Images Lexaria(纳斯达克:LEXX)表示,计划进行一项动物研究,评估其产品Deterhetech-GLP-1的配方,其中包括诺和诺德的semaglutide或利拉鲁肽,以及Deterhetech CBD治疗减肥和糖尿病。脱水技术-GLP-1是一种GLP-1药物,采用该公司的脱水技术药物输送技术进行处理,而脱水技术-CBD是大麻二酚产品。

The company will be testing the products alone and in combination for weight loss and blood glucose level control, according to a statement. Lexaria said the GLP-1 formulations to be tested will include Novo Nordisk’s (NVO) semaglutide or liraglutide. Semaglutide is marketed by Novo Nordisk under the names Wegovy, Ozempic and Rybelsus.

根据一份声明,该公司将单独或联合测试这些产品的减肥和血糖水平控制。Lexaria表示,要测试的GLP-1制剂将包括诺和诺德(Novo Nordisk)的semaglutide或利拉鲁肽。Semaglutide由诺和诺德以Wegovy,Ozempic和Rybelsus的名称销售。

Liraglutide is sold under the names Victoza and Saxenda. More on Lexaria Bioscience Corp. Lexaria slips despite FDA nod to test blood pressure drug Lexaria submits IND to begin Phase 1b study of DehydraTECH-CBD Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings data for Lexaria Bioscience Corp.

利拉鲁肽以维克托萨和萨森达的名字出售。关于Lexaria Bioscience Corp.的更多信息。Lexaria下滑,尽管FDA批准测试血压药物Lexaria提交IND开始脱水技术CBD的1b期研究,寻求Lexaria Bioscience Corp.的Alpha定量评级。Lexaria Bioscience Corp.的历史收益数据。

Financial information for Lexaria Bioscience Corp. .

Lexaria Bioscience Corp.的财务信息。

推荐阅读

Lexaria为下一项GLP-1人体试验研究授予合同

BioSpace 2024-03-07 22:24

Lexaria开始关于糖尿病和减重动物的Weight-A24-1研究

BioSpace 2024-03-05 22:29

Lexaria宣布360万美元注册直接发行,根据纳斯达克规则在市场上定价

BioSpace 2024-02-15 21:41

seekingalpha

412篇

最近内容 查看更多

2024年迄今为止表现最好的10只生物技术股

2024-03-07

Creative Medical股价上涨18%,脆性1型糖尿病候选疗法获授予孤儿药称号

2024-03-06

Cyclacel Pharmaceuticals获得290万美元的研发税收抵免

2024-03-06

相关公司查看更多

Lexaria Bioscience

药物输送技术研发商

立即沟通

产业链接查看更多